183434-02-8

Basic information

• Product Name: (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester
• Synonyms: (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester
• CAS NO: 183434-02-8
• Molecular Formula: C₁₄H₁₇NO₆
• Molecular Weight: 295.28788
• Mol File: 183434-02-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: 187.6-189 °C
• Boiling Point: 610.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.35±0.1 g/cm3(Predicted)
• PKA: 9.19±0.60(Predicted)
• CAS DataBase Reference: (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester(183434-02-8)
• EPA Substance Registry System: (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester(183434-02-8)

Safety Data

• Hazardous Substances Data: 183434-02-8(Hazardous Substances Data)

Usage

Description

(S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester is a complex organic compound characterized by its unique pyrano[3,4-c]pyridine carboxylic acid structure with a propyl ester derivative. It features an ethyl and hydroxy group, which may contribute to its potential interactions with biological systems. (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester's structural features, including its ring system and carboxylic acid functionality, suggest it may have pharmaceutical or medicinal applications. However, further research is necessary to explore its specific properties and possible uses.

Uses

Used in Pharmaceutical Industry:
(S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester is used as a potential pharmaceutical candidate for [application reason] due to its structural features that may allow for specific interactions with biological targets.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-4-Ethyl-4-hydroxy-3,8-dioxo-3,4,7,8-tetrahydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester is used as a compound with potential therapeutic applications, leveraging its unique structural elements for the development of new drugs.

Upstream product

• 183434-00-6 propyl (S)-4-ethyl-3,4-dihydro-4-hydroxy-8-methoxy-3-oxo-1H-pyrano[3,4-c]pyridine-6-carboxylate 
• 99-11-6 citrazinic acid 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 183433-62-7 1-(2,6-dichloropyridin-4-yl)propan-1-one 
• 183433-74-1 5-Benzyloxymethyl-4-(1-hydroxy-1-hydroxymethyl-propyl)-6-methoxy-pyridine-2-carboxylic acid propyl ester 
• 183433-75-2 5-Benzyloxymethyl-4-((S)-1-hydroxy-1-hydroxymethyl-propyl)-6-methoxy-pyridine-2-carboxylic acid propyl ester 
• 183433-63-8 2,6-dichloro-4-(2-ethyl-1,3-dioxolan-2-yl)pyridine 
• 183433-64-9 6-chloro-4-(2-ethyl-1,3-dioxolan-2-yl)-2-methoxypyridine 
• 183433-65-0 6-Chloro-4-(2-ethyl-[1,3]dioxolan-2-yl)-2-methoxy-pyridine-3-carbaldehyde 
• 183433-66-1 [6-Chloro-4-(2-ethyl-[1,3]dioxolan-2-yl)-2-methoxy-pyridin-3-yl]-methanol 
• 194999-55-8 (S)-4-Ethyl-3,4-dihydroxy-8-methoxy-3,4-dihydro-1H-pyrano[3,4-c]pyridine-6-carboxylic acid propyl ester 
• 183433-67-2 3-Benzyloxymethyl-6-chloro-4-(2-ethyl-[1,3]dioxolan-2-yl)-2-methoxy-pyridine 
• 183433-72-9 5-Benzyloxymethyl-6-methoxy-4-(1-methylene-propyl)-pyridine-2-carboxylic acid propyl ester 
• 183433-96-7 5-Benzyloxymethyl-4-((S)-1-formyl-1-hydroxy-propyl)-6-methoxy-pyridine-2-carboxylic acid propyl ester 

Downstream Products

• 110351-94-5 (4S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione 
• 86639-52-3 7-ethyl-10-hydroxycamptothecin 
• 97682-44-5 irinotecan 

Relevant articles and documents

METHOD OF SYNTHESIZING CAMPTOTHECIN-RELATING COMPOUNDS

The present invention is to prepare efficiently 2'-amino-5'-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.